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OBJECTIVES: There is a growing understanding of the complexity of interplay between renal and cardio-
vascular systems in both health and disease. The medical profession has adopted the term “cardio-
renal syndrome” (CRS) to describe the pathophysiological relationship between the kidney and heart 
in disease. CRS has yet to be formally defined and described by the veterinary profession and its 
existence and importance in dogs and cats warrant investigation. The CRS Consensus Group, com-
prising nine veterinary cardiologists and seven nephrologists from Europe and North America, sought 
to achieve consensus around the definition, pathophysiology, diagnosis and management of dogs and 
cats with “cardiovascular-renal disorders” (CvRD). To this end, the Delphi formal methodology for 
defining/building consensus and defining guidelines was utilised.
METHODS: Following a literature review, 13 candidate statements regarding CvRD in dogs and cats were 
tested for consensus, using a modified Delphi method. As a new area of interest, well-designed stud-
ies, specific to CRS/CvRD, are lacking, particularly in dogs and cats. Hence, while scientific justifica-
tion of all the recommendations was sought and used when available, recommendations were largely 
reliant on theory, expert opinion, small clinical studies and extrapolation from data derived from other 
species.
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1992, Beardow & Buchanan 1993, Polzin 2011, 2013) and cats 
(Buchanan 1992, Riesen et al. 2007, Chakrabarti et al. 2013) 
as an important source of morbidity and mortality (Fleming 
et al. 2011), the interaction between the two systems has yet to 
be formally defined and described by the veterinary profession. 
The CRS Consensus Group, comprising 16 academic and clini-
cal experts, including 9 veterinary cardiologists and 7 veterinary 
nephrologists from Europe and North America, was created with 
the goal of developing consensus, definitions and recommenda-
tions for CRS in dogs and cats. The panelists were chosen based 
on expertise in the areas of cardiology, hypertension and nephrol-
ogy and recognition as contributing experts in their respective 
fields. The group was intentionally selected as representative of 
academic veterinarians from Western Europe and North  America, 
based on their ability and interest in participating in this project 
and diplomate status in one or more of the clinical specialties 
(American and European Colleges of Veterinary Internal Medi-
cine [ACVIM, ECVIM, respectively, or the European College 
of Veterinary Clinical Pathology and Toxicology). Other criteria 
involved in this selection process included past participation in 
related consensus statement development (International Renal 
Interest Society [IRIS], ACVIM Hypertension Consensus State-
ment and ACVIM Consensus Statement on Diagnosis and Treat-
ment of Canine Mitral Valve Disease). An advanced degree and/
or research experience in nephrology/cardiology were also con-
sidered to be desirable attributes. All authors are board-certified 
and are currently involved in research in their area of specialty, 
and 10 of 16 have advanced degrees (3 MS, 6 PhD, 1 MD).
The objectives of the group were to 1) define CRS as it pertains 
to the dogs and cats as veterinary patients, 2) recommend diag-
nostic testing and evaluation of CRS, 3) provide general guide-
lines for the treatment of patients with CRS with an emphasis on 
the potential interplay between the two organ systems and 4) to 
increase awareness of CRS as an important disease entity in vet-
erinary medicine deserving of further research. Early on, the CRS 
Consensus Group chose to refer to CRS in veterinary patients 
as “cardiovascular-renal disorders (CvRD)”, such that the vas-
culature as well as the heart was included, and because, based on 
INTRODUCTION
A complex interplay between the rena l and cardiovascular sys-
tems exists in both health and disease. In humans, the pathologi-
cal interactions between these two organ systems are increasingly 
deserving of further definition, classification and understanding. 
The term “cardiorenal syndrome (CRS)” defined as “disorders of 
the heart and kidneys whereby acute or chronic dysfunction in 
one organ may induce acute or chronic dysfunction of the other” 
(Ronco et al. 2010) has been adopted by physicians to describe 
this pathological interplay. CRS is subdivided into the following 
five types: type 1, involving acute worsening of heart function 
leading to kidney injury, such as that occurring in patients with 
acute congestive heart failure (CHF); type 2, involving chronic 
disease of the heart leading to kidney injury, such as that occurring 
in patients with chronic heart failure; type 3, involving acute wors-
ening of kidney function leading to heart injury, such as that in 
patients with acute kidney injury (AKI); type 4, involving chronic 
kidney disease (CKD) leading to heart injury; and finally, type 
5, involving systemic disease(s) leading to simultaneous injury of 
both the heart and kidney, such as that occurring in patients with 
sepsis, systemic hypertension or amyloidosis (Ronco et al. 2010). 
Although the epidemiology, diagnosis, prevention and manage-
ment of CRS in humans have been proposed (Ronco et al. 2010, 
McCullough et al. 2013, Braam et al. 2014, Ronco & Di Lullo 
2014), the clinical relevance, time course of onset and pathophysi-
ological mechanisms of CRS are incompletely understood (Braam 
et al. 2014). The only recognised facts are (i) blood volume, vaso-
motor tone and haemodynamic stability are dependent on the 
cardiovascular and renal systems and (ii) the interactions between 
the two systems (Bock & Gottlieb 2010). The concept of CRS 
combines the cardiovascular system and kidneys as part of a single 
homeostatic cardiorenal axis, which challenges cardiologists and 
nephrologists who treat heart and kidney failure, respectively, to 
consider this in a complete perspective.
Although kidney and heart diseases are commonly recog-
nised in domestic dogs (Detweiler & Patterson 1965, Buchanan 
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RESULTS: Of the 13 statements, 11 achieved consensus and 2 did not. The modified Delphi approach 
worked well to achieve consensus in an objective manner and to develop initial guidelines for CvRD.
DISCUSSION: The resultant manuscript describes consensus statements for the definition, classification, 
diagnosis and management strategies for veterinary patients with CvRD, with an emphasis on the 
pathological interplay between the two organ systems. By formulating consensus statements regard-
ing CvRD in veterinary medicine, the authors hope to stimulate interest in and advancement of the 
understanding and management of CvRD in dogs and cats. The use of a formalised method for consen-
sus and guideline development should be considered for other topics in veterinary medicine.
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and 5 being undecided. Among the 16 rating scores, the low-
est and highest scores for each statement were discarded. This 
resulted in 14 scores, such that no score could be <5 and the 
median value must have been ≥7 in order for a statement to be 
described as having achieved consensus. Two rounds of consensus 
rating were performed. At the start of the 2-day meeting, group 
members were introduced to the rating method and they dis-
cussed and modified the statements. Following this discussion, 
the first round of rating was conducted and scores for each state-
ment were reviewed. Then, the group broke out into four differ-
ent subgroups, each of which were led by a steering committee 
member (Subgroup 1: CEA, VLF, JE; Subgroup 2: CB, VC, DJP, 
AMV; Subgroup 3: SLV, JDB, NVI, GFG; Subgroup 4: MAO, 
TF, LDC, NSM) with the task of revising the statements, based 
on the results and feedback from the first round of rating. Sub-
sequently, the entire group reconvened for further discussion 
and revision, and by the end of the meeting, final wording for 
each of the 13 statements had been constructed. Over the next 
several weeks, members were able to further consider the state-
ments, using a web-based platform accessible to all the 16 mem-
bers. Eight weeks after conclusion of the meeting, a second and 
final round of rating was carried out, using the online platform, 
with identical rating instructions, scoring procedures and crite-
ria for consensus. For those statements that achieved consensus, 
the strength of consensus was determined by the lowest value 
of the 14 individual rating scores, wherein strong consensus was 
defined as having a lowest individual score ≥7 and good consen-
sus defined as a lowest individual score of either 5 or 6. The final 
rating results, statements and supporting information were com-
piled into a draft manuscript by the steering committee, which 
was then reviewed and edited by all group members before sub-
mission for publication.
RESULTS
Definition, classification and pathophysiology 
of CvRD
experience in cardiovascular and renal diseases, the clinical mani-
festations of CvRD in the dog and cat are expected to be widely 
varied among individuals and between species, precluding their 
description as a single clinical syndrome. 
It is important to emphasise that the manifestations of cardiac 
and renal diseases differ between species, thereby limiting the 
validity of deriving information from human data for veterinary 
application, as well as comparisons between dogs and cats. Car-
diac disease in humans is primarily related to hypertension and 
coronary artery disease, which is different from dogs ( primary 
valvular disease, dilated cardiomyopathy and heartworm dis-
ease) and cats (hypertrophic cardiomyopathy, other myopathies 
and, to a lesser degree, systemic hypertension). Likewise, human 
renal diseases (glomerular disease, diabetic nephropathy, hyper-
tensive nephropathy, nephrosclerosis, interstitial nephritis and 
polycystic kidney disease (Maschio et al. 1996, Hou et al. 2006)) 
do not correlate exactly to those seen in veterinary patients 
(dogs: glomerular disease, pyelonephritis, acute tubular necro-
sis, tubulointerstitial disease (Macdougall et al. 1986) and cats: 
idiopathic chronic end-stage kidney disease, most often charac-
terised by tubulointerstitial fibrosis, typically of unknown origin 
(Chakrabarti et al. 2013)). Nevertheless, there are some aspects 
of the diseases and their pathophysiology that warrant interspe-
cies comparison and application of human findings to veterinary 
medicine. 
METHODOLOGY
The CRS Consensus Group included a 5-person steering and 
publication committee, comprising a chairman (JLP) and 4 
additional steering members (CEA, CB, MAO, SLV), as well as 
an 11-member rating group. The chairman and steering group 
oversaw a PubMed search for relevant biomedical literature, pub-
lished between 1995 and 2013. The committee then drafted a 
review of CvRD that included 13 summary statements. The 13 
statements spanned four different subtopics, including defini-
tion, classification and pathophysiology (Subgroup 1 - 2 state-
ments); epidemiology, clinical aspects and diagnosis (Subgroup 
2 - 3 statements); biomarkers and imaging (Subgroup 3 - 5 
statements); and management (Subgroup 4 - 3 statements) of 
CvRD. The literature review and statements were discussed dur-
ing a 2-day meeting of the entire CRS Consensus Group in April 
2013. During this meeting, the entire CRS Consensus Group 
revised the documents and summary statements to coalesce 
around points of agreement. 
The ultimate goal of the CRS Consensus Group was to pro-
duce a consensus document describing CvRD in the dog and cat. 
A modified Delphi method, based on guidelines by the Haute 
Autorité de santé (HAS or French National Authority for Health) 
(Haute Autorité de Santé 2010), was utilised to evaluate whether 
or not each of the 13 draft summary statements achieved formal 
consensus. According to the method, each group member scored 
each statement from 1 to 9, depending on the strength of their 
agreement with the statement, with 1 being that the statement is 
totally inappropriate, 9 being the statement is totally appropriate 
Statement 1: Cardiovascular-renal disorders (CvRD) are defined 
as disease, toxin or drug-induced structural and/or functional dam-
age to the kidney and/or cardiovascular system, leading to disrup-
tion of the normal interactions between these systems, to the ongoing 
detriment of one or both. (Good consensus; median  rating, 8; 
range 5–9)
Statement 2: CvRD includes subgroups CvRD
H
, CvRD
K
 and 
CvRD
O
 to reflect renal disease/dysfunction emanating from a dis-
ease involving the cardiovascular system; cardiovascular disease/
dysfunction secondary to renal disease and concurrent impairment 
of both systems caused by concurrent primary cardiovascular and 
kidney disease or “other” disease processes, drugs, toxins or toxicants 
that affect both systems, respectively. The three categories can be fur-
ther subdivided into stable disease (S) or unstable disease (U) based 
on the patient’s clinical presentation. (Good consensus; median 
 rating, 7; range, 6–9)
J. L. Pouchelon et al.
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The concept of CRS, which involves a bidirectional pathway of 
injury wherein disease of either organ directly or indirectly con-
tributes to injury of the other (Fig 1), presents a broader view of 
fluid and haemodynamic homeostasis compared to a more tra-
ditional viewpoint, which considers kidney and cardiovascular 
impairment as separate pathophysiological entities. In the follow-
ing section, the epidemiology and pathophysiology of each of the 
three classes of CvRD will be discussed.
Epidemiology and pathophysiology of CvRDH
CvRD
H 
refers to kidney injury or dysfunction emanating from 
a primary disease process involving the cardiovascular system. 
Potential mechanisms of CvRD
H
 include decreased kidney per-
fusion secondary to decreased cardiac output; activation of neu-
roendocrine systems, namely, the renin-angiotensin-aldosterone 
system (RAAS) and sympathetic nervous system (SNS); genera-
tion of reactive oxygen species by abnormal or injured endothe-
lial tissue and passive venous congestion of the kidney (Table 1) 
(Haase et al. 2013, McCullough et al. 2013). Acute reduction 
in cardiac output can lead to decreased glomerular filtration 
rate (GFR), increased serum creatinine and blood urea nitrogen 
(BUN) and decreased urine output (Liang et al. 2008). In both 
humans and animals, increases in creatinine as little as 0·3 mg/dL 
(26·5 µmol/L) are regarded as indicative of AKI (Jose et al. 2006, 
Harison et al. 2012, International Renal Interest Society 2014). 
The IRIS has proposed diagnostic criteria for AKI in dogs and cats 
(Table 2) (International Renal Interest Society 2014). This grad-
ing system encompasses a continuum of functional and parenchy-
mal damage from its least to its most severe  manifestations. The 
clinical presentation of AKI includes prerenal and postrenal con-
ditions that may be independent or combined with intrinsic renal 
injury depending on the functional origin, extent and duration of 
the conditions inciting the disease. Mild AKI, defined as a serum 
creatinine concentration >1·6 mg/dL (1·7–2·5; >141 µmol/L; 
Each of these two statements achieved good consensus. A key 
concern of both CRS and CvRD is the way the kidney and car-
diovascular systems interact, including the potential for harm 
along three different axes, from kidney to cardiovascular system, 
from cardiovascular system to kidney and from outside disease 
processes to both. In instances where disease coexists in both 
organ systems, it can be difficult to determine the directionality 
of CvRD or if concurrent primary disease coexists. The concept 
of CvRD emphasises the inter-related functions of the two organ 
systems and encourages a complete and early investigation of 
the function of the heart in instances of kidney disease and the 
function of the kidney in instances of heart disease. In human 
medicine, CRS is a relatively new, but evolving, field of medi-
cal study, while the understanding of the inter-relationship in 
animals (CvRD) is in its infancy. Therefore, it is expected that 
the proposed definition and classification scheme for CvRD in 
dogs and cats will require reassessment and modification as more 
veterinary research involving CvRD is performed.
Epidemiology, clinical aspects and diagnosis 
of CvRD
Statement 3: Despite the lack of specific data regarding the patho-
physiology of CvRD in veterinary medicine, available literature 
suggests the likelihood that CvRD pathophysiology in animals 
shares some common patterns with human CRS, namely, the com-
plex interplay of haemodynamic changes, neurohormonal activa-
tion and reactive oxygen species, to name a few. (Good consensus; 
median rating, 8; range, 5–9)
This statement achieved good consensus. The understanding 
of CRS in humans is incomplete (Ronco & Di Lullo 2014), and 
in veterinary medicine, the existence and exact nature of CvRD is 
largely speculative. Nevertheless, there are known disease aetiolo-
gies in the dog and cat that are characterised by detrimental inter-
actions between the kidney and cardiovascular systems (Table 1). 
Table 1. Aetiology of cardiovascular-renal disorders (CvRD) in dogs and cats
CvRD class Aetiology
CvRDH Systemic hypertension leading to glomerular disease
Cardiac shock, low cardiac output and systemic hypotension leading to decreased renal perfusion, azotaemia and acute kidney injury
Systemic arterial thromboembolism leading to renal infarction
Heartworm infection or caval syndrome leading to glomerulonephritis or AKI, respectively
Passive congestion of the kidney during heart failure*
CvRDK Kidney-mediated systemic hypertension leading to increased afterload, left ventricular hypertrophy, worsening mitral or aortic insufficiency, 
arrhythmias, vasculopathy or retinopathy
Volume overload leading to congestion or systemic hypertension
Hypokalaemia or hyperkalaemia leading to cardiac arrhythmias
Reduced renal clearance of drugs (e.g. digoxin) leading to toxicity
Uraemic hypodipsia, anorexia or emesis leading to volume depletion and reduced cardiac output and perfusion
Uraemic pericarditis
Activation of the renin-angiotensin-aldosterone axis leading to sodium and water retention, cardiac and vascular remodelling or congestion
Anaemia secondary to chronic kidney disease leading to volume overload and reduced cardiac tissue oxygenation*
CvRDO Septic or neoplastic emboli leading to renal and cardiac infarction
Gastric dilation and volvulus leading to cardiac arrhythmias and azotaemia
Infectious disease (e.g. Trypanosoma cruzi)
Glycogen storage disease leading to glycogen deposition in the kidneys and heart
Amyloidosis leading to amyloid deposition in the kidney and cardiac tissues*
*Causes that are proposed, possible or suspected. See text for description of the different CvRD classes. 
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tained, have been shown to worsen outcome in humans with 
heart disease (Jose et al. 2006) and in dogs and cats with vari-
ous underlying disease processes (Harison et al. 2012). Whether 
142–220), is detected in dogs or cats treated for heart failure 
(Goutal et al. 2010). These relatively modest values, even when 
they fail to exceed the relevant  laboratory  reference range, if sus-
Progressive
Cardiovascular
Dysfunction
Renin Angiotensin Aldosterone System Activity
Volume
Anemia
Oxidative
Stress
Apotosis
FibrosisRenal Blood Flow and GFR
Progressive
Kidney
Dysfunction
ContractilityAfterloadVentricular
hypertrophy
Sympathetic Nervous
System Activity
CongestionCardiac OutputSystemic Hypertension
Glomerular Pressure
FIG 1. Postulated mechanisms underlying the relationship between heart failure (HF) and renal dysfunction. Blue arrows indicate pathways by which 
HF may lead to renal failure. Red arrows indicate pathways by which renal failure may lead to HF. The relative importance of these mechanisms (and 
additional mechanisms not discussed) is not known (i.e. boxes are not drawn to scale). The figure has been modified to include systemic hyperten-
sion, an important vascular component to CvRD. From Bock. JS. Gottlieb, SS. 2010, adapted with permission. GFR, glomerular filtration rate, RAAS, 
renin-angiotensin-aldosterone system, SNS, sympathetic nervous system.
Table 2. International Renal Interest Society (IRIS) grading criteria for acute kidney injury (AKI) in dogs and cats (adapted 
with permission from Borgarelli et al. (2001)
AKI grades Serum creatinine Clinical description
I <1·6 mg/dL 
(<140 µmol/l)
Non-azotaemic AKI: 
a.  Documented AKI: (Historical, clinical, laboratory or imaging evidence of acute kidney injury, clinical oliguria/
anuria, volume responsiveness†)…and/or
b. Progressive non-azotaemic increase in serum creatinine; ≥0.3 mg/dL (≥ 26.4 µmol/l) within 48 hours
c. Measured oliguria (<1 ml/kg/hr) or anuria over 6 hours
II 1·7–2·5 mg/dL 
(141–220 µmol/L)
Mild AKI: 
a. Documented AKI and static or progressive azotaemia
b.  Progressive azotaemic increase in serum creatinine; ≥0.3 mg/dL (≥ 26.4 µmol/l) within 48 hours), or volume 
responsiveness†
c. Measured oliguria (<1 ml/kg/h) or anuria over 6 hours
III 2·6–5·0 mg/dL 
(221–439 µmol/L)
Moderate to severe AKI: 
a. Documented AKI and increasing severities of azotaemia and functional renal failure
IV 5·1–10·0 mg/dL 
(440–880 µmol/L)
V >10·0 mg/dL 
(>880 µmol/L)
Each grade of AKI is further sub-graded on the basis of oliguria, non-oliguric (NO) or oligoanuria (O), as well as any requirement for renal replacement therapy (RRT).
†Volume responsive is an increase in urine production to >1 ml/kg/h over 6 hours; and/or decrease in serum creatinine to baseline over 48 hours)
J. L. Pouchelon et al.
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Bernay et al. 2010), thereby increasing the potential for develop-
ment of primary kidney disease over time as well as cumulative 
exposure to potentially nephrotoxic drugs, such as diuretics and 
ACE inhibitors (ACEIs). ACEIs, ubiquitous in managing heart 
failure and hypertension, are known to be nephrotoxic at very 
high (70×) dosages and when administered to volume-depleted 
dogs (MacDonald et al. 1987). Although not known to be directly 
nephrotoxic, potent loop diuretics, such as furosemide, at high 
dosages, are associated with volume contraction and worsening 
kidney function, suggesting their possible role in potentiation 
of ACEI-induced nephrotoxicity (Steimle et al. 1997, Schrier 
et al. 2004). Additionally, loop diuretics stimulate the RAAS 
system (Lantis et al. 2014), with well-documented pathological 
effects on the kidney (Francis et al. 1990). New evidence indi-
cates that furosemide, by increasing sodium reaching the distal 
tubule, increases adenosine secretion, which, through vasoactive 
mechanisms, worsens renal function and contributes to diuretic 
resistance (Vallon et al. 2008, Lazzarini et al. 2012). In order to 
reduce worsening kidney function in people with heart failure, 
alternatives to diuresis are being explored (Costanzo et al. 2007, 
Givertz et al. 2007). However, there are contradictory studies, as 
well. A large retrospective study of human heart failure patients 
showed that the expected significant rise in serum creatinine with 
furosemide administration, although statistically significant, was 
very small (0·11 mg/dL; 9·7µmol/L [0·4%]) over 5 days of hospi-
talisation) and explained little of the variation in serum creatinine 
concentration and estimated GFR (El-Refai et al. 2011). Impor-
tantly, these results agree with a smaller prospective study on the 
effects of intravenous furosemide at varied dosages and admin-
istration methods (Felker et al. 2011). A timely review of this 
material details the conflicting evidence in virtually all aspects of 
CRS development, prevention and treatment in humans (Laz-
zarini et al. 2012). However, the authors were able to conclude 
from the data available that “… acute CRS prevention and treat-
ment might be considered among the main targets of acute HF 
management.” and that “…loop diuretics should be adminis-
tered at the minimal dose sufficient to optimize volume status, 
and relieve signs and symptoms of congestion, without induc-
ing an excessive reduction in intravascular volume, which could 
result in hypotension and/or renal dysfunction”. The dilemma of 
inconsistent results regarding the benefit vs. harm of loop diuret-
ics has been recently addressed (Hanna & Deschamps 2014). 
Based on reviewing data at hand, these clinician scientists believe 
that a subset of CHF patients are worsened by aggressive diuresis. 
These authors conclude that “… congestion is at the center of 
acute (heart failure) syndromes. Aggressive decongestion greatly 
improves renal and myocardial flow and ventricular loading con-
ditions. This allows renal function to improve enough to sustain 
diuresis with lower diuretic doses. This also allows the patient to 
tolerate lower systemic pressure without compromise of myocar-
dial or renal perfusion. The combination of 2 particular factors 
predicts a poor renal tolerance of acute diuresis: (1) non-dilated 
left and right ventricles with a steep pressure-volume relation-
ship (e.g. de novo acute [heart failure], diastolic [heart failure]) 
and (2) no or minimal peripheral edema. Patients with severe 
edema usually tolerate aggressive diuresis, especially if they have 
these changes indicate permanent structural renal damage remains 
to be determined in dogs and cats. The authors recommend that 
when treating animals with acute CHF, the lowest diuretic dos-
age required to resolve signs of congestion should be prescribed 
and renal values carefully assessed. However, there is no robust 
evidence that the development of a serum creatinine of >1·6 g/
dL (>141µmol/L) in cats and dogs with heart failure results in 
poor clinical outcomes. This would require an adequately pow-
ered prospective clinical trial that has not been undertaken. As 
such, a serum creatinine of >1·6 g/dL (>141µmol/L) should not 
be used as an indicator to withhold necessary therapy in a patient 
with poorly controlled heart failure.
In humans, additional mechanisms beyond a decreased car-
diac output and glomerular pressure are known to lead to kidney 
injury. The hydrostatic glomerular filtration gradient, defined 
as the difference between glomerular blood pressure and cap-
sular hydrostatic pressure, is heavily influenced by systemic 
venous pressure. Congestion of kidney tissue, due to poor car-
diac function and elevated systemic venous pressure, preferen-
tially increases capsular pressure, decreases glomerular filtration 
pressure and rate and substantially decreases kidney function 
(Dupont et al. 2011). In humans with heart failure, incomplete 
resolution of venous congestion is a primary cause of worsening 
renal function (Testani et al. 2011, Guazzi et al. 2013) and is 
associated with poorer patient outcomes (Mullens et al. 2009). 
The reader can recognise the dilemma in trying to balance the 
negative effect of diuretic actions on arterial renal perfusion vs. 
the positive effect on venous renal congestion. 
The RAAS, and in particular angiotensin II, precipitates and 
mediates oxidative and cytokine-mediated injury, inflammation 
and cell death (Mitani et al. 2013). The resulting endothelial 
dysfunction and reactive oxygen species (ROS) formation pro-
vides an important link between kidney and cardiac dysfunction 
(Fig 1) (Braam et al. 2014). CHF and accompanying elevated 
cytokine levels, reduced iron intake and absorption and sup-
pression of angiotensin-converting enzyme (ACE) (angiotensin 
II is an erythropoietin secretagogue) contribute to anaemia in 
people (Pallazzuoli et al. 2008, Chalhoub et al. 2011). Chronic 
inflammation is also thought to decrease sensitivity to erythro-
poietin and, along with kidney injury and diminished erythropoi-
etin production, contribute to anaemia (Chalhoub et al. 2011). 
Diminished or ineffective circulating erythropoietin reduces 
haemoglobin and its antioxidant properties and contributes to 
CvRD
H
, through increased oxidative stress and apoptosis of kid-
ney and cardiac cells (Silverberg et al. 2006). The importance of 
haemoglobin in CvRD
H
 is a subject of debate, as erythropoietin 
therapy used to increase haemoglobin concentration in human 
patients with heart failure was not associated with improved 
patient outcome (Jackevicius et al. 2014).
The prevalence of CvRD
H
 in dogs and cats is unknown; how-
ever, the incidence of primary kidney disease increases with age 
(Ross & Osborne 2006, Polzin 2011). Thus, older animals with 
cardiovascular disease are at additional risk of developing primary 
kidney disease and CvRD
O
. Advances in medical therapy for 
CHF have resulted in improved life expectancy (Ettinger et al. 
1998, Haggstrom et al. 2008, The BENCH Study Group 2008, 
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kidney dysfunction, with reduced drug clearance, and can lead 
to signs of toxicity that include arrhythmias, hypotension and 
worsening myocardial function. Fluid volume and haemody-
namic status are virtually always abnormal in patients with severe 
kidney disease (Much & Wilcox 1982, Polzin 2011). Uraemic 
patients who are anorexic and hypodipsic and vomiting are likely 
to be even further volume-depleted with a resultant reduction 
in cardiac output. Kidney injury can also lead to systemic vol-
ume overload that contributes to congestion, especially in those 
animals with coexisting cardiac diseases, such as valve disease, 
dilated cardiomyopathy, diastolic dysfunction (hypertrophic car-
diomyopathy and hypertensive heart disease) and severe anae-
mia (Wilson et al. 2010). The anaemia of CKD unlikely plays a 
significant role here, as it is typically low-grade, unless there are 
other factors at work (chronic inflammation, neoplasia, etc) in 
addition to CKD. SHT is a common sequela to CKD and can 
result in myocardial hypertrophy and dysfunction in both cats 
(Chetboul et al. 2003, Henik et al. 2004, Carlos Sampedrano 
et al. 2006) and dogs (Misbach et al., 2011). Finally, azotaemia 
itself may have adverse effects on cardiac myocytes (Mall et al. 
1990). 
Epidemiology and pathophysiology of CvRDO
CvRD
O 
refers to kidney and cardiovascular injury or dysfunction 
emanating from either a primary disease process outside the two 
systems or instances in which primary kidney and cardiovascular 
diseases coexist (Table 1). Examples of the former include sepsis 
and infectious diseases (Mehta et al. 2013) and an example of the 
latter includes an animal with primary glomerular disease and 
myxomatous mitral valve degeneration. Once primary kidney 
and cardiovascular diseases are established, CvRD
O
 pertains to 
the previously described interactions between the two systems 
that may accelerate injury to either or both. At present, these 
interactions are poorly defined and there is a lack of convincing, 
published evidence for CvRD
O
 in dogs and cats. 
Clinical staging and evaluation of CvRD 
The diagnosis of either a kidney disease or a cardiovascular dis-
ease requires the integration of information obtained from mul-
tiple sources. The presenting complaint, medical history and 
physical examination can alert the clinician to the kidney, heart 
or vasculature as deserving of further diagnostic testing. Blood 
and urine testing, non-invasive blood pressure measurement and 
radiographic and ultrasonographic imaging are the diagnostic 
tools routinely available for both kidney and cardiovascular dis-
eases. Accurate diagnosis and staging are essential to the detec-
tion of CvRD and in designing subsequent therapeutic plans. 
Staging of Heart Disease in CvRD
Statement 4: When considering the potential involvement of the 
heart in CvRD, the most appropriate classification system is the 
International Small Animal Cardiac Health Council (ISACHC) 
system. (No consensus; median rating, 7; range, 2–9)
good plasma refill time. Conversely, in patients without severe 
peripheral edema and with poorly compliant, small ventricles, 
the preload volume is not dramatically increased but the pre-
load pressure (left ventricular end-diastolic pressure) is increased. 
Therefore, these patients have pulmonary edema despite being 
preload volume dependent. Diuresis may be poorly tolerated in 
the absence of peripheral edema, leading to a large change in car-
diac output and, as a result, renal failure and hypotension.” They 
go on to further conclude that the best therapy is careful diuretic 
administration in conjunction with vasodilator therapy.
In dogs and cats, the existence of CvRD
H
 is indirectly sup-
ported by the observation that kidney dysfunction increases with 
severity of heart disease. In a retrospective study (Nicolle et al. 
2007), 50% of 124 dogs with chronic valvular heart disease were 
azotaemic, and this finding was present in 70% of dogs with the 
most severe stages of disease. In dogs with severe disease, both 
serum BUN and creatinine were higher and GFR was lower (by 
nearly one-half ) vs. dogs with milder heart disease. As clearly 
indicated by the authors, these differences in azotaemic status 
and GFR between mild versus severe heart failure stages could be 
related to both the effect of drugs used for the medical manage-
ment of heart disease (e.g. ACEIs and diuretics) and the effect of 
the valvular disease itself on renal function, thus illustrating the 
need of further investigations to establish the direct and indi-
rect cause-effect relationships between the progression of heart 
disease and the development of renal dysfunction. Similarly, in 
a retrospective study of cats with hypertrophic car diomyopathy 
(Gouni et al. 2008), azotaemia was present in 59% of cases. 
Again, as stated by the authors, further prospective studies are 
needed to document the pathophysiological events underlying 
the occurrence of azotaemia in feline hypertrophic cardiomy-
opathy and to determine the extent to which heart and vascular 
diseases (and drugs used in their treatment) directly or indirectly 
induce kidney injury. Diseases of the vasculature are included in 
the proposed definition of CvRD and include disorders such as 
systemic hypertension (SHT) (Fig 1). Hypertension-induced glo-
merular damage in veterinary patients is well described (Wehner 
et al. 2008, Surman et al. 2012, IRIS Canine GN Study Group 
Diagnosis Subgroup et al. 2013) and among the various proposed 
aetiologies of CvRD (Fig 1), SHT is one of the most plausible. 
Epidemiology and pathophysiology of CvRDK
CvRD
K 
refers to cardiovascular injury or dysfunction emanating 
from a primary disease process involving the kidney. There is little 
direct evidence for CvRD
K
 in dogs and cats (Carlos Sampedrano 
et al. 2006, Wilson et al. 2010). Likewise, in humans, there is 
more knowledge and clinical experience concerning CvRD
H
 
than for CvRD
K
 (Ronco et al. 2008). There are both known and 
suspected negative effects of kidney disease on the cardiovascu-
lar system (Bagshaw et al. 2013, Tumlin et al. 2013, Ronco & 
Di Lullo 2014). For example, electrolyte abnormalities, such as 
hyperkalaemia, can complicate both AKI and CKD and are asso-
ciated with cardiac arrhythmias (Bagshaw et al. 2013). Various 
drugs used for the treatment of cardiac disease, such as digoxin, 
enalapril and atenolol, undergo renal excretion and cause  primary 
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a therapeutic intervention” (Biomarkers Definitions Working 
Group 2001). Ideally, any particular biomarker not only reflects 
the severity of the pathological process but can also be used to 
assess the risk of adverse events, predict outcome and guide 
therapy. In veterinary medicine, biomarkers generally refer to 
substances that can be measured in either blood or urine. The 
consensus group deliberated as to whether or not existing bio-
markers for kidney or cardiovascular disease can be used to spe-
cifically diagnose, predict outcome or guide therapy in CvRD. 
Statement 6: Currently, there are no biomarkers specific for 
CvRD
H
. Consequences of heart disease or cardiac therapy on the 
kidneys should be evaluated with traditional tests of kidney func-
tion/damage as well as newer biomarkers as developed. Cardiac 
biomarkers such as N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) and cardiac troponin-I (cTnI) may be useful for the 
establishment of heart disease or cardiac injury. (Good consensus; 
median rating, 7.5; range, 6–9)
This statement achieved good consensus. Biochemical and 
biomarker assays for assessment of kidney function are widely 
used and accepted (Table 3). For example, serum creatinine is 
This statement did not achieve consensus due to three individual 
rater scores that were <5. The ISACHC system classifies animals 
on the basis of limited indices, such as clinical signs of heart failure 
and the existence or absence of cardiac hypertrophy (International 
Small Animal Cardiac Health Council 1999). One weakness of 
the ISACHC system is its non-specificity regarding anatomical 
or aetiological diagnosis. Nevertheless, alternative systems, such 
as the American College of Veterinary Internal Medicine sys-
tem, specifically designed for dogs with myxomatous mitral valve 
degeneration (Atkins et al. 2009), fail to account for important 
cardiovascular abnormalities that can develop in CvRD, including 
systemic hypertension, diastolic and systolic dysfunction, arrhyth-
mias and alterations in biomarkers. In the context of CvRD, the 
ISACHC or similar systems are, in isolation, incomplete means 
to categorise involvement of the cardiovascular system. Additional 
potential diagnostic and staging tools, such as cardiac imaging and 
biomarkers, are discussed in later sections.
Staging of acute kidney injury and CKD in CvRD
Statement 5: When considering the potential involvement of 
the kidney in CvRD, the most appropriate classification for acute 
 kidney injury and CKD are the IRIS classification systems. (Good 
consensus; median rating, 8.5; range, 6–9)
This statement achieved good consensus. In human and vet-
erinary medicine, the term AKI reflects a broad spectrum of acute 
insults to the kidney. The IRIS systems for AKI (Table 2) and CKD 
(International Renal Interest Society 2014) were deemed useful in 
assessing potential kidney involvement in CvRD. The IRIS systems 
encompass a continuum of damage from mild to severe, including 
several key indices of kidney function. AKI is identified by an acute 
rise in serum creatinine concentration, the sudden appearance of 
glucosuria or cylindruria or the sudden decrease in urine concen-
trating ability. Each grade of AKI is further subdivided based on 
the current nature of urine production. Other biochemical abnor-
malities that often accompany AKI, including microalbuminuria 
and increased urine protein-to-creatinine ratio, are accounted for 
in the IRIS system. Based on the IRIS guidelines, relatively small 
changes in serum creatinine concentrations can signal AKI, and 
the severity of AKI can fluctuate as the patient improves, wors-
ens or transitions to CKD. The IRIS system for CKD is based 
on markers of kidney function, including serum creatinine and 
proteinuria. The CKD guidelines also incorporate systemic arterial 
blood pressure, which is an important pathophysiological mecha-
nism of CRS (Fig 1) (Ronco & Di Lullo 2014). Thus, as opposed 
to existing cardiovascular staging systems, the IRIS guidelines for 
kidney disease were considered sufficiently complete for descrip-
tion of kidney injury and disease in CvRD.
Biomarkers and imaging of CvRD 
Biomarkers of CvRD
Biomarkers have been defined as “a characteristic that is objec-
tively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to 
Table 3. Traditional and novel blood and urine tests to 
assess various kidney functions
Kidney parameter Test
Glomerular 
filtration rate
Traditional 
blood and 
urine tests
Serum creatinine
Plasma clearance techniques 
Potential 
novel 
markers
Symmetric dimethylarginine (SDMA)
Glomerular 
permselectivity
Traditional 
blood and 
urine tests
Serum albumin
Urine protein: creatinine ratio
Microalbuminuria
Potential 
novel 
markers
Urine immunoglobulin G
Tubular damage 
or dysfunction
Traditional 
blood and 
urine tests
Serum creatinine
Serum electrolytes
Serum bicarbonate
Urine glucose
Urine amino acids
Urine protein: creatinine ratio
Urine specific gravity
Potential 
novel 
markers
Urine N-acetyl B-D-glucosaminidase 
(NAG)
Urine retinol-binding protein (RBP)
Urine gamma-glutamyl transpeptidase 
(GGT)
Urine cystatin-C
Urine kidney injury molecule-1 (KIM-1)
Urine neutrophil gelatinase-associated 
lipocalin (NGAL)
Urinary clusterin
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all three are at least partially dependent on kidney function for excre-
tion. Therefore, it is difficult to know whether increased natriuretic 
peptide and cTn1 concentrations reflect cardiac injury, normal vari-
ation or decreased excretion. Cardiac troponin is a part of the actin-
myosin complex and, in healthy individuals, serum or plasma cTnI 
concentration should be very low. Studies reveal that cTnI concen-
trations are increased in dogs and cats with primary and secondary 
cardiac disease and predict clinical outcome (Oyama & Sisson 2004, 
Fonfara et al. 2010, Hezzell et al. 2012, Langhorn et al. 2013). This 
suggests that cTnI might be able to detect subclinical cardiac injury 
due to CvRD
K
; however, interpretation of cTnI assay is clouded by 
lack of information regarding the time course and magnitude of 
cTnI release in many disease conditions.
Imaging in CvRD
Statement 8: Thoracic radiography is recommended to assess the 
presence or absence of congestive heart failure, and echocardiog-
raphy is recommended to assess cardiac morphology, lesions, and 
to estimate relevant haemodynamic parameters. (Strong consensus; 
median rating, 8; range, 7–9)
This statement achieved strong consensus. Diagnostic imag-
ing plays an important role in the assessment of cardiac func-
tion. Radiographic and ultrasound imaging modalities provide 
morphological expressions of the anatomy and function. 
These findings and complementary data are derived from his-
tory, physical examination, electrocardiography and laboratory 
analyses of blood and urine. Together, this combination of data 
allows determination of the presence, cause, severity and conse-
quences of heart disease. Typically, the objective of cardiotho-
racic radiographic examination is to detect changes in the cardiac 
silhouette, vascular structures and lung parenchymal pattern, 
 ultimately determining if there are signs of cardiac disease or 
CHF. Echocardiography is used to assess cardiac morphology and 
function. Doppler echocardiography, including spectral Doppler, 
color flow Doppler, tissue Doppler and more advanced modali-
ties such as strain, strain rate and 2D speckle tracking, provides 
specific information about the velocity and direction of blood 
flow and myocardial motion (Chetboul 2010, Chetboul &Tissier 
2012). Longitudinal changes in radiographic and echocardio-
graphic indices help determine morbidity and predict mortality 
in dogs and cats with heart disease (Lord et al. 2011, Reynolds 
et al. 2012). Thus, radiographic and echocardiographic imag-
ing modalities represent two cornerstones of cardiac diagnostic 
examination. The reader is referred to several excellent reviews 
of cardiothoracic radiographic and echocardiographic interpreta-
tion for more information (Thomas et al. 1993, Buchanan & 
Bucheler 1995, Litster & Buchanan 2000, Guglielmini et al. 
2009, Chetboul 2010, Schober 2010, Chetboul & Tissier 2012). 
Statement 9: Renal imaging is recommended to improve diagno-
sis, prognosis and guide potential therapies in CvRD. Conventional 
abdominal radiographs and ultrasound are recommended to help 
detect morphological abnormalities and determine underlying aeti-
ology. (Good consensus; median rating, 8; range, 6–9)
used to assess GFR and serum and urine albumin and total pro-
tein concentrations are used to assess glomerular permselectivity. 
Urine glucose and amino acid concentrations are used to assess 
proximal tubular function, while serum electrolytes and bicar-
bonate concentrations reflect the kidney’s ability to maintain 
electrolyte and acid-base balance. Finally, urine specific gravity 
allows assessment of renal concentrating ability. The validity 
of these markers is well established in both primary acute and 
chronic kidney injury settings (Polzin 2011), and although their 
specificity to differentiate primary kidney injury vs. CvRD
H
 is 
untested, these traditional markers are likely adequately sensi-
tive to detect kidney dysfunction due to CvRD
H
. The search for 
novel biomarkers of kidney injury and markers specific to either 
CRS or CvRD is a topic of considerable interest in both human 
and veterinary patients (Maddens et al. 2011, Monti et al. 2012, 
Tvarijonaviciute et al. 2012, Cobrin et al. 2013, Daure et al. 
2013, De Loor et al. 2013, Kai et al. 2013, Rossi et al. 2013, 
Segev et al. 2013). An abbreviated list of potential markers for 
various aspects of kidney function is presented in Table 3.
Statement 7: Currently, there are no specific biomarkers for 
CvRD
K
. Consequences of kidney disease on the heart (CvRD
K
) 
should be evaluated with the cardiac biomarkers N-terminal pro-
B-type natriuretic peptide (NT-proBNP) and cardiac troponin-I 
(cTnI). Biomarkers of kidney function/damage are available but 
need to be evaluated further in the setting of cardiac disease. (No 
consensus; median rating, 7; range 3–8).
This statement did not achieve group consensus due to two 
individual scores that were <5. The most common biomarker tests 
used to assess cardiovascular disease are N-terminal pro-B-type natri-
uretic peptide (NT-proBNP), B-type natriuretic peptide (BNP), 
N- terminal pro-atrial natriuretic peptide (NT-proANP) and cardiac 
troponin I (cTnI). Although these biomarkers have been well stud-
ied in the setting of primary cardiovascular diseases such as cardio-
myopathy and valve disease (DeFrancesco et al. 2007, Boswood et al. 
2008, Connolly 2010, Oyama et al. 2013), their validity is less well 
established than that of the biomarkers used for assessment of kidney 
function, such as creatinine and urine specific gravity. Diagnostic 
guidelines involving cardiac biomarkers are weakened by significant 
“grey-zones” that affect the ability to stratify patient populations on 
the basis of assay results alone (Oyama et al. 2013). The natriuretic 
peptides, including NT-proBNP, BNP and NT-proANP, are con-
stitutively produced by the myocardium and help regulate plasma 
volume, sodium excretion and vasomotor tone in both health and 
disease (Potter et al. 2009). Thus, this system is inherently up- or 
down-regulated on a moment-to-moment basis and varies with 
stage of disease as well, potentially leading to erroneous conclusions. 
Additionally, clinically relevant individual and breed variation is 
recognised, both within and among healthy and diseased individuals 
(Kellihan et al. 2009, Sjostrand et al. 2014). Moreover, few studies 
on cardiac biomarkers have been performed in settings applicable to 
CvRD
K
. In animals with apparently normal cardiac function, but 
with acute or chronic renal injury, serum or plasma concentrations 
of NT-proBNP, BNP and cTnI are increased (Lalor et al. 2009, 
Schmidt et al. 2009, Sharkey et al. 2009, Miyagawa et al. 2013), as 
J. L. Pouchelon et al.
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lesions in cardiac, vascular, renovascular, ocular and central ner-
vous system tissues. Systolic pressure >160 mmHg indicates pro-
gressive risk of end- or target-organ damage (International Renal 
Interest Society 2014). With regard to the canine kidney, SHT 
can result in increased rate of renal injury, proteinuria, decreased 
GFR, increased incidence of uraemic crisis and worsened mortal-
ity. (Jacobs et al. 2003) In the cat, the causal relationship between 
hypertension and kidney disease is less clear. It is known that 
hypertension is a risk factor for proteinuria, which, in turn, is a 
risk factor for worsening kidney disease (Syme et al. 2006, Jepson 
et al. 2007, Chakrabarti et al. 2012). In a correlative study of 
laboratory variables and pathological lesions in the kidneys of 
cats with CKD, proteinuria was associated with interstitial fibro-
sis and glomerular hypertrophy, whereas higher time-averaged 
systolic blood pressure was associated with glomerulosclerosis 
and hyperplastic arteriosclerosis (Chakrabarti et al. 2013). Car-
diovascular injury secondary to SHT is well accepted in humans 
(Frohlich et al. 1992, Drazner 2011) and includes left ventricu-
lar concentric hypertrophy, arrhythmia, haemorrhage, vascular 
and myocardial fibrosis and remodelling, development of aor-
tic insufficiency, mainly diastolic but also systolic dysfunction, 
and heart failure. Controlled studies are lacking in dogs and cats, 
but observational studies have described several left ventricular 
hypertrophic patterns (Snyder et al. 2001, Chetboul et al. 2003, 
Henik et al. 2004, Carlos Sampedrano et al., 2006), reversal of 
left ventricular hypertrophy with blood pressure control (Sny-
der et al. 2001), retinal vasculopathy (Maggio et al. 2000), aortic 
 dissection and aortic insufficiency related to proximal aortic dila-
tion (Wey & Atkins 2000, Misbach et al. 2011) and heart failure 
(Wey & Atkins 2000, Chetboul et al. 2003).  Additionally, two- 
dimensional tissue Doppler imaging studies have demonstrated 
that SHT in both cats and dogs is associated with  diastolic and, 
to a lesser extent, systolic dysfunction, independent of the pres-
ence of myocardial hypertrophy (Carlos Sampedrano et al. 2006, 
Misbach et al. 2011).
The reported prevalence of SHT in dogs and cats with CKD 
varies considerably, depending on the population selected, the 
stage of kidney disease and the blood pressure measuring tech-
nique employed, but CKD is assuredly present in a considerable 
percentage of the population at risk for SHT (Brown et al. 2007). 
SHT is estimated to occur in 60–90% of dogs and 20–65% of 
cats with kidney disease (Stepien 2014). The relationship of SHT 
with mitral valve disease in dogs is incompletely understood, and 
blood pressure varies by stage of disease (Petit et al. 2013). The 
minimum database in animals with SHT should include a CBC, 
serum biochemistry panel, serum thyroxine concentration, uri-
nalysis and abdominal ultrasound (Brown et al. 2007). Ruling 
out endocrine or other secondary causes of SHT may require 
additional disease-specific assays. 
Disorders that cause systemic hypotension can also cause 
kidney and cardiovascular injury. Hypotension, due to severe 
volume depletion, low cardiac output or collapse of systemic vas-
cular resistance, reduces tissue perfusion and GFR and activates 
maladaptive neurohormonal responses (Morales et al. 2002). 
Systemic hypotension, defined as systolic pressure <90 mmHg, 
has been associated with acute heart failure, occurring in 16% 
This statement achieved good consensus. Various imaging 
modalities are available to assess the kidney and urinary system. 
Plain orthogonal radiographic examination, in particular, the 
ventrodorsal view, allows determination of kidney size and num-
ber and may provide evidence of unilateral or bilateral abnormal-
ities or differences in kidney size, shape and position, as well as 
detection of presence of radiodense uroliths (Rivers & Johnston 
1996, Polzin 2011, Bartges 2012). Ultrasonic examination of the 
kidneys and urinary tract allows visualisation of renal parenchy-
mal abnormalities, renal pelvic and ureteral dilation, renal blood 
flow abnormalities, infarcts, cysts, mineralisation and uroliths 
and helps achieve a diagnosis of pyelonephritis, lymphoma or 
ethylene glycol toxicosis (Rivers & Johnston 1996, Lamb 1998, 
Debruyn et al. 2012). The biggest limitation to ultrasonic evalu-
ation is its lack of sensitivity to minor alterations in the anatomy 
of renal pelvises and ureters (Lamb 1998). Contrast studies, such 
as the excretory urogram, or more advanced techniques, such 
as computerised tomography or magnetic resonance imaging 
with contrast, may provide additional information regarding the 
patency of the urinary system and the presence of abnormalities 
(Ohlerth & O’Brien 2007, Chang et al. 2011, Fonseca-Matheus 
et al. 2011, Schmidt et al. 2012). The reader is referred to sev-
eral excellent reviews of kidney and urinary tract imaging for 
additional information (Rivers & Johnston 1996, Lamb 1998, 
Debruyn et al. 2012).
Systemic blood pressure measurement in CvRD
Statement 10: As the kidney and heart are two organs at risk for 
damage due to systemic hypertension, and as kidney disease is often 
associated with systemic arterial hypertension, systemic arterial 
blood pressure should be systematically monitored in both kidney 
and cardiovascular diseases. (Good consensus; median rating, 8; 
range, 5–9)
This statement achieved good consensus. One of the best-
described interactions between the kidney and cardiovascular 
system involves their intimate roles in regulation of arterial blood 
pressure. SHT represents the best example of a mechanism by 
which CvRD
H
, CvRD
K
 and CvRD
O 
may occur. Because hyper-
tension negatively affects both organ systems, blood pressure 
measurement is routinely recommended in patients with kidney 
or cardiovascular disease, and the reader is referred to several 
excellent reviews regarding the measurement of blood pressure 
in dogs and cats (Brown et al. 2007, Syme 2011, Stepien 2014). 
SHT is also commonly associated with diseases other than kidney 
disease, such as hyperadrenocorticism, hyperaldosteronism, pha-
eochromocytoma, hyperthyroidism, hypothyroidism, canine dia-
betes mellitus and canine acromegaly (Brown et al. 2007). SHT 
is likewise associated with certain therapeutic agents, such as glu-
cocorticoids, mineralocorticoids, erythropoietin and phenylpro-
panolamine (Brown et al. 2007). SHT can also be stress-induced 
(i.e. white-coat hypertension) or may occur in the absence of 
other identifiable disease (i.e. idiopathic, primary or “essential” 
hypertension) (Belew et al. 1999, Marino et al. 2011). As in 
humans, SHT in dogs and cats is a  potential cause of  irreversible 
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Treatment of AKI and CKD involves a combination of paren-
teral fluids, the infrequent use of diuretics for treatment of vol-
ume overload and hyperkalaemia, antihypertensive agents, ACEI, 
gastrointestinal protectants, alkalizing agents, erythropoiesis-
stimulating agents, phosphate binders and dietary adjustment. 
A key aspect to the treatment of both AKI and CKD is main-
tenance of adequate intravascular volume and pressure to allow 
sufficient renal perfusion, while avoiding fluid overload and elec-
trolyte imbalance. Contrarily, a major goal in the treatment of 
CHF is reduction of intravascular volume and hydrostatic pres-
sure, through the use of diuretics and other offloading therapies. 
Thus, essential to both cardiac and kidney diseases is the need to 
restore and maintain normal fluid balance, which is often a par-
ticularly difficult aspect of therapy (DeFrancesco 2008).
The pharmacological management of cardiovascular and renal 
diseases contributes to CvRD. Excessive reduction in vascular 
volume in cases of CHF or excessive increases in vascular vol-
ume in cases of AKI or CKD can lead to adverse effects in the 
other organ system. Achieving the correct balance is, of course, 
more difficult when the heart and kidneys are concomitantly 
dysfunctional. Treatment of CvRD involves the recognition and 
simultaneous, frequent evaluation of subtle changes in kidney or 
heart function and an understanding of how the pathophysiol-
ogy of one disease can interact with and impact the function of 
the other. An important aspect of managing CvRD is to treat 
the primary cause of clinical signs, while attempting to minimise 
clinically relevant worsening of the function of the other organ. 
Management guidelines for CvRD are almost exclusively based 
on theory and expert opinion, as clinical trials specific to CvRD 
are lacking.
Management of CvRDH
Statement 11: Unstable CvRD
H 
, such as in instances of acute 
CHF, typically requires hospitalisation to restore or improve car-
diac function and to alleviate congestive or low output signs while 
simultaneously evaluating risk of kidney dysfunction. Standard 
acute CHF therapy that includes diuretics, ACEI, vasodilators 
and positive inotropes might need to be adjusted based on frequent 
assessment of hydration, renal function biomarkers, electrolytes, 
blood pressure, body weight and urine output. (Strong consensus; 
median rating, 8; range, 8–9)
This statement achieved strong consensus. In cases of CVRD
H
, 
the therapeutic margin is small as the use of diuretics and ACEI 
can have adverse effects on renal function and overly aggressive 
diuresis with excessive dehydration should be avoided. Strategies 
to minimise the development of azotaemia during treatment of 
acute CHF include reducing the total daily dosage (dosage and/
or frequency of administration) of parenteral diuretics, use of 
venous or arterial vasodilators to augment reduction of preload 
and afterload and use of pimobendan or intravenous dobutamine 
infusion to increase cardiac output and kidney perfusion. A small 
proportion of clinicians withhold or minimise the use of ACEI 
during in-hospital treatment for acute CHF, as diuretic-induced 
volume depletion might increase the risk for ACEI-induced renal 
of dogs and cats during hospitalisation (Goutal et al. 2010). In a 
study of dogs with mitral valve disease, systolic BP was inversely 
correlated to clinical severity of disease. This indicates the poten-
tial for a cardiac disease-related and/or treatment-induced vascu-
lar complication (hypotension). Kidney damage would occur if 
hypotension is severe enough to produce renal under-perfusion. 
(Petit et al. 2013). Treatment of SHT is discussed under Manage-
ment of CvRD.
Management of CvRD
Treatment of CvRD is challenging, as the treatment for kid-
ney disease often relies upon fluid therapy and close attention 
to the amount and quality of protein and phosphorous intake 
(Roudebush et al. 2010, Monaghan et al. 2012, Polzin 2013). In 
contrast, animals with heart failure typically undergo diuresis and 
receive protein supplementation, especially in those with signs 
of congestion (pulmonary oedema or third space effusions) and/
or cardiac cachexia, respectively (Atkins et al. 2009, Borgarelli & 
Haggstrom 2010). Also important to the management of CvRD 
are an understanding of the tendency for azotaemia to develop 
in animals receiving diuretics, the benefits and risks of ACEI in 
the setting of concurrent kidney and cardiovascular disease and 
the potential influence of SHT on both organ systems (Nicolle 
et al. 2007, Atkins et al. 2009, Brewer et al. 2012). Thus, both 
the heart and kidney are affected by abnormal intravascular fluid 
volume, systemic blood pressure and commonly employed treat-
ments such as diuretics, vasodilators and supplemental fluids used 
to correct these imbalances. These factors potentially affect the 
interaction between these two organ systems (DeFrancesco 2008). 
The clinical staging and management of heart failure (Bor-
garelli et al. 2001, Atkins et al. 2009, Ferasin 2009, Atkins & 
Haggstrom 2012, DeFrancesco 2013), AKI and CKD (Lees et al. 
2005, Roudebush et al. 2010, Polzin 2011, 2013, Ross 2011, 
Vaden 2011, Bartges 2012, Monaghan et al. 2012) have been 
extensively described. In brief, heart failure is the condition 
wherein the diseased heart fails to provide adequate cardiac out-
put or can only do so in the presence of elevated venous  filling 
pressures and the risk of congestion (Colluci & Braunwald 2005).
Treatment of acute and chronic CHF involves the use of 
diuretics, including furosemide and hydrochlorothiazide (Atkins 
et al. 2009, Goutal et al. 2010, Atkins & Haggstrom 2012); 
vasodilators, including ACEI (Atkins et al. 2009, Goutal et al. 
2010, Atkins & Haggstrom 2012), amlodipine (Quinones et al. 
1996, Snyder et al. 2001), diltiazem (Gelzer et al. 2009), nitro-
glycerin, hydralazine and nitroprusside (Atkins 2001, Atkins & 
Haggstrom 2012); neurohormonal blocking agents, including 
ACEI, spironolactone (Atkins et al. 2009) and beta blockers, 
such as atenolol and propranolol (Rush et al. 2002, Goutal et al. 
2010); and positive inotropes such as digoxin, dobutamine and 
pimobendan (Atkins et al. 2009, Goutal et al. 2010, MacGregor 
et al. 2011, Atkins & Haggstrom 2012). AKI and CKD are con-
ditions wherein the diseased kidney fails to adequately excrete 
waste products and to maintain fluid volume and electrolyte bal-
ance, resulting in volume and electrolyte abnormalities, azotae-
mia and clinical signs of uraemia, when severe.
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 appropriate fluid balance and urine production in patients with-
out frank heart failure. Even in the absence of clinical signs of 
heart failure, fluid supplementation should be closely monitored 
to avoid precipitation of congestion and discontinued if respi-
ratory signs are noted or if weight gain becomes excessive. In 
instances where signs of over-hydration and congestion occur, 
fluid administration should be discontinued and the addition of 
diuretics considered. 
Patients with CvRD
K
 might necessitate a cautious and step-
wise approach to fluid replacement or maintenance with a selec-
tion of a fluid type relatively low in sodium, along with careful 
monitoring of body weight, respiratory rate and effort, arterial 
blood pressure and for development of jugular venous distension 
or ascites. Resting (i.e. non-panting) respiratory rates >40 breaths 
per minute have been shown to be a sensitive indicator of early 
pulmonary congestion (oedema) (Schober et al. 2010, Ohad et al. 
2013, Ljungvall et al. 2014). Inadvertent fluid overloading puts 
additional stress on the cardiovascular system and increases the 
risk of congestion. With the exception of cases of systemic hypo-
tension, dopamine is not indicated for management of AKI due to 
lack of proven efficacy and potential for adverse side effects, such 
as worsening of renal function, arrhythmias and sinus tachycardia. 
(Chertow et al. 1996, Lauchske et al. 2006, Wohl et al. 2007) 
The use of renal replacement therapies (such as haemodialysis and 
ultrafiltration) that enable fine control over intravascular volume 
in CvRD
K
 is intriguing (Acierno 2011, Cowgill 2011, Eatroff 
et al. 2012), but requires additional study. 
Important aspects of managing all forms of CvRD
Statement 13: In addition to specific management strategies for 
CvRD
H
 or CvRD
K 
, particular attention should be directed towards 
the following when managing any form of CvRD: 1) identification 
and treatment of elevated blood pressure as per IRIS recommenda-
tions; 2) stepwise titration of dosages of diuretics, ACEI, inotropes 
and/or fluids with frequent monitoring of renal function, body 
weight, hydration, electrolyte status, and systemic blood pressure 
(i.e. performed and rechecked within 3–5 days following initia-
tion or dose adjustment of these drugs); 3) proper nutrition, with 
respect to reduced dietary sodium and phosphate and appropriate 
protein and caloric intake. (Strong consensus; median rating, 8; 
range, 8–9)
This statement achieved strong consensus. In dogs and cats 
with CvRD, the goal is to maintain systolic blood pressure <160 
mmHg in an attempt to prevent or minimise target-organ dam-
age (International Renal Interest Society 2014). As blood pres-
sure increases to above 160 mmHg, the risk to target organs 
increases and treatment is recommended, with or without evi-
dence of target-organ damage. In both dogs and cats, expert 
opinion advocates for dietary sodium restriction with concur-
rent pharmacological therapy (Brown et al. 2007, International 
Renal Interest Society 2014). In dogs, the first choice therapy 
is an ACEI, which is titrated to effect while monitoring renal 
function. In cats, the first choice therapy is the calcium channel 
blocker amlodipine (International Renal Interest Society 2014). 
injury (Atkins et al. 2009). If ACEIs are withheld or withdrawn 
during the acute phase, they are typically (re)introduced once 
the initial episode of acute CHF is resolved, and the animal is 
discharged to home care. In cases of severe volume depletion, 
(re)introduction of diuretics or ACEIs should occur only after 
the animal’s hydration status has improved or at the recurrence 
of clinical signs of congestion. One potential therapeutic strat-
egy involving the various ACEIs, such as enalapril, benazepril, 
ramipril and imidapril, is the administration of a dosage at the 
lower end of the recommended range followed by evaluation of 
hydration status and renal function before a decision whether 
to titrate either drug to the higher end of the dosage range. Free 
choice of water should always be provided to such patients, 
unless vomiting or diminished mental status dictates otherwise. 
In severely dehydrated animals or in those with substantial azo-
taemia or uraemia following diuretic therapy, intravenous or 
subcutaneous fluids, with consideration as to a particular fluid’s 
sodium and potassium content, should be carefully administered. 
The use of feeding tubes should be considered in anorexic ani-
mals to provide both nutrition and sodium-free hydration. Anti-
aldosterone agents such as spironolactone are often prescribed in 
the chronic phases of CHF treatment (Bernay et al. 2010), and 
the potential for additional beneficial effects such as reduction of 
cardiac, renal and vascular remodelling in patients with CvRD 
merits further investigation (Ovaert et al. 2010). Serum potas-
sium concentrations should be closely monitored – especially 
when spironolactone is used in conjunction with ACEI or in the 
setting of renal dysfunction.
Management of CvRDK
Statement 12: Unstable CvRD
K
, such as in instances of acute 
kidney injury (AKI), typically requires hospitalisation to improve 
renal function and to restore fluid and electrolyte balance while 
simultaneously evaluating the risk of cardiac dysfunction. In addi-
tion to standard management of AKI, particular attention should 
be directed towards 1) appropriate fluid, diuretic and/or antihy-
pertensive treatment based on hydration status; these therapies are 
aimed at restoration and maintenance of normal fluid balance and 
blood pressure while avoiding sodium and fluid overload and 2) 
re-evaluation of concurrent cardiac medications and possible dos-
age adjustment. (Strong consensus; median rating, 8; range, 7–9)
This statement achieved strong consensus. This agreement 
stems from the clinical experiences of the authors, in which 
diuretic use is recognised as a double-edged sword, saving lives by 
reducing congestion, but, conversely, being overused in coughing 
dogs or dyspneic cats with or at risk of developing AKI. Since 
the diagnosis of CHF can be elusive, these pets may undergo 
diuresis appropriately, when suffering from CHF, or inappropri-
ately when not. The authors also note that potent loop diuretics, 
usually furosemide, are sometimes prescribed at inappropriately 
high dosages for extended periods, with harmful drying of airway 
secretions and/or worsening azotaemia. 
In cases with clinically significant dehydration, paren-
teral fluid replacement is often provided in an effort to regain 
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on azotaemia; therefore, careful dietary planning with the sup-
port of a veterinary nutritionist or internist might be helpful. 
Dietary supplements, such as omega-3 fatty acids, are occasion-
ally used in animals with CvRD (Freeman et al. 1998, Smith 
et al. 2007, Roudebush et al. 2010, Polzin 2011), both as antioxi-
dants and appetite stimulants, but their safety and efficacy have 
not been rigorously demonstrated (Lenox & Bauer 2013).
CONCLUSION
Although still very early, there is growing evidence indicating 
that the pathological states, CRS and CvRD, respectively, may 
be important in both humans and animals. While some aspects 
of CvRD clearly exist in dogs and cats, the existence of oth-
ers is merely speculative. There is clearly much to do in iden-
tifying, proving and understanding this subject. This consensus 
statement is meant to increase the awareness of and codify the 
definition, classification and means of identification and provide 
provisional information on management of CvRD. Additionally, 
this manuscript aims to stimulate and provide a framework for 
research and communication on CvRD and to encourage collab-
orative studies involving cardiologists and nephrologists. 
The CRS Consensus Group is made up of a diverse group of 
experts in veterinary cardiology and nephrology, whose efforts 
resulted in 11 (of 13 proposed) CvRD consensus statements for 
dogs and cats. The authors recommend that this consensus docu-
ment be modified, as new information regarding CvRD is avail-
able. During their discussions and deliberations, the authors were 
continuously reminded that the heart, vessels and kidney are 
inexorably linked, not only anatomically but also by principles 
at the foundations of physiology, pathology and medicine, and 
that consideration of a single cardiovascular-renal axis has great 
merit. The authors hope that this manuscript stimulates interest; 
advances knowledge of CvRD, its existence and importance; and 
ultimately contributes to the ability of veterinarians to success-
fully manage dogs and cats with, or at risk for, this condition.
The modified Delphi methodology, used to build the consen-
sus and develop guidelines for CvRD, provided a formal, predict-
able and objective scaffold for this project. This method or others 
like it warrant consideration for developing future consensus 
statements for veterinary medicine.
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